Skip to main content
Download PDF

Roles of sphingosine-1-phosphate signaling in cancer

Cancer Cell International volume 19, Article number: 295 (2019) Cite this article

Abstract

The potent pleiotropic lipid mediator sphingosine-1-phosphate (S1P) participates in numerous cellular processes, including angiogenesis and cell survival, proliferation, and migration. It is formed by one of two sphingosine kinases (SphKs), SphK1 and SphK2. These enzymes largely exert their various biological and pathophysiological actions through one of five G protein-coupled receptors (S1PR1–5), with receptor activation setting in motion various signaling cascades. Considerable evidence has been accumulated on S1P signaling and its pathogenic roles in diseases, as well as on novel modulators of S1P signaling, such as SphK inhibitors and S1P agonists and antagonists. S1P and ceramide, composed of sphingosine and a fatty acid, are reciprocal cell fate regulators, and S1P signaling plays essential roles in several diseases, including inflammation, cancer, and autoimmune disorders. Thus, targeting of S1P signaling may be one way to block the pathogenesis and may be a therapeutic target in these conditions. Increasingly strong evidence indicates a role for the S1P signaling pathway in the progression of cancer and its effects. In the present review, we discuss recent progress in our understanding of S1P and its related proteins in cancer progression. Also described is the therapeutic potential of S1P receptors and their downstream signaling cascades as targets for cancer treatment.

Background

The vast sphingolipid family includes two prominent bioactive lipids, ceramide and sphingosine-1-phosphate (S1P). The latter, which is membrane derived, is produced through ceramidase-catalyzed conversion of ceramide to sphingosine and its subsequent phosphorylation by sphingosine kinases (SphKs) [1]. Export of intracellularly produced S1P requires the action of some transporters, particularly ATP-binding cassette (ABC) C1, ABCG2, and spinster 2 (Spns2) [2, 3]. S1P exerts a multitude of effects on cell physiology and pathology through five S1P receptors (S1PRs) [4]. These receptors are coupled to distinct G protein α subtypes, including Gq, Gi, and G12/13 [5]. Activation of the S1PRs and the consequent stimulation of the associated G protein regulates distinct signaling pathways, including AKT and ERK1/2 [6]. Together, these cascades mediate S1P signaling, which is involved in numerous diseases, including cancer, atherosclerosis, kidney disease, and immunological disorders [7,8,9]. In recent years, considerable progress has been made in elucidating the role of S1P signaling in cancer. In particular, Besim Ogretmen highlighted the role of S1PR-dependent and -independent signaling in cancer cell growth, tumor metastasis, and drug resistance [10]. In addition, some studies have found that S1PR2 plays a dual role in the progression of cancer by modulating a diverse range of downstream second messengers [11, 12]. Therefore, targeting of S1P signaling is likely to be a novel therapeutic strategy for cancer.

In this review, we discuss S1P signaling and its involvement in cancer progression. We additionally describe the potential value of S1P signaling pathway targeting in cancer therapy.

S1P, a bioactive lipid mediator

More than 25 years ago, Sarah Spiegel discovered that S1P is a biologically active lipid mediator that is abundant in plasma, regulates many physiological processes, and acts as a signaling molecule in cells [13, 14]. Since then, more and more researchers have explored S1P synthesis, degradation, and receptors, all of which collaborate to regulate S1P expression and signaling inside and outside cells [15]. Collectively, these findings prove that S1P acts as a signaling molecule in cells. The validation of S1P and its related molecules has boosted lipid research [16].

S1P biosynthesis and homeostasis

S1P is derived from intracellular ceramide. Ceramide is first converted into sphingosine by the enzyme ceramidase, with sphingosine subsequently phosphorylated by SphK to produce S1P [1]. Thus far, two SphK isotypes—SphK1 and SphK2—have been identified [17]. The former is present in nearly every cell type [18] and is localized to the cytosol close to the cell membrane, where it participates in the transport of S1P via “inside-out” signaling [19]. “Inside-out” signaling refers to the process through which S1P produced inside cells is exported by transporters and signals through extracellular S1PRs [2, 15], which will be described later in this review. It is through this process that we can find a large number of S1Ps in some cancers, such as breast, gastric, and pancreatic [20,21,22,23]. Because SphK2 has mainly been reported in the nuclei and mitochondria, S1P produced by SphK2 may be not as effective as S1P extracellularly produced by SphK1 [24]. Furthermore, although S1P is structurally no different whether produced by SphK1 or SphK2, it exerts different functions in the body according to where it has been produced [15]. Thus, S1P in the nuclei acts as a histone deacetylase inhibitor and epigenetically regulates gene transcription [24, 25]. SphK2 is highly expressed and plays complex roles in highly diverse organs, including the kidney, liver, and brain. For example, S1P in the nucleus and mitochondrion controls the transcription of genes critical to epigenetics [26, 27]. Moreover, SphK2 may participate in mast cell function, with SphK2 inhibition ameliorating immunosuppression-related disorders, such as chronic infections and/or cancers [28,29,30].

Despite its role as a pleiotropic lipid mediator, S1P cannot freely pass through plasma membranes to the extracellular space due to the presence of a polar head group. S1P export thus requires the involvement of a transporter [15], and several such proteins have been identified in recent years [19, 31]. Indeed, some ABC transporters have been found to export S1P, including ABCC1 [2, 31]. The S1P transporter function of ABCC1 was first identified in mast cells [32]. ABCC1 and the related transporter ABCG2 transport S1P out of estrogen receptor-positive breast cancer cells in response to the nongenomic actions of estrogen [33]. More recently, Spns2, a member of the major facilitator superfamily that lacks the typical ATP-binding motif [34, 35], was determined by two independent groups to be an S1P transporter [3, 35]. Both research groups, which identified the S1P-transporting function of Spns2 in zebrafish, showed that a mutation in Spns2 led to cardia bifida (duplicated hearts). The phenotype could be rescued using exogenous S1P [33, 36].

S1P is present in higher concentrations in blood and lymph than in tissue [37]. In addition, S1P-degrading enzymes are more active in tissue, where they play a major role in limiting the levels of S1P. Two enzymes reduce the level of S1P: S1P lyase and S1P phosphatase [38]. S1P lyase irreversibly decomposes S1P by cleaving its C2–C3 bond [39]. Some studies have shown that S1P lyase expression is significantly downregulated in human colon cancer tissues versus normal adjacent tissues [40, 41], an indicator of the importance of low S1P levels. As part of a recycling pathway, S1P phosphatase hydrolyzes the phosphate group from S1P to produce sphingosine, which is then converted by ceramide synthase to ceramide [42].

Taken together, SphK, S1P transporter, and its degrading enzymes all regulate S1P gradation and signaling (Fig. 1), which control normal physiological function and may play a role in cancer progression.

Fig. 1
figure 1

Biosynthesis of S1P. S1P is generated from sphingosine (SPH) by two sphingosine kinases (SphK1 and SphK2) in the catabolic pathway. SphK1 mainly exists in the cytosol, but SphK2 exists in the nuclei and mitochondria. S1P produced by SphK1 is exported to the extracellular space, where it exerts various functions associated with cancer via S1P receptor (S1PR). S1P produced by SphK2 is thought to play important roles in intracellular functions

Full size image

S1P receptors and agonists/antagonists

S1P, whether produced by SphK1 or SphK2, owes almost all of its bioactive pleiotropic effects on cell survival, migration, angiogenesis, and lymphangiogenesis and immune cell recruitment, all processes that may be involved in cancer, to S1PR1–5, which are S1P-specific G protein-coupled receptors (GPCRs) [4, 43]. These five receptors are canonical members of the rhodopsin subfamily of GPCRs (class A). Their characteristic features comprise an intracellular C terminus, seven helical transmembrane domains, and a 30 to 50 residue extracellular N terminus. Deorphanization work has recently determined that S1PRs, similar to a larger-than-expected number of GPCRs (~ 40 so far), are selectively activated by bioactive lipids, such as leukotrienes, prostaglandins, free fatty acids, endocannabinoids, and phospholipids (including lysophosphatidic acid [LPA] and lysophosphatidylserine) [44, 45]. Closely related to the S1PRs are LPA (LPA1–3) receptors [15, 46], which bind a lipid with a similar structure to S1P. The receptors in this subfamily show considerable sequence homology to each other and, although closely related to endocannabinoid receptors, are divergent from the other lipid-activated GPCRs.

Knowledge of the structure and mechanism of S1PRs may help to shed light on the diseases in which they participate, including atherosclerosis, cancer [7, 40, 47,48,49], diabetes [50], congenital disorders [36], kidney diseases [8], and immunological diseases [9]. Recent efforts have yielded diverse compounds, both agonists and antagonists and with varying degrees of selectivity, that affect S1PRs [51] (Table 1). Notably, major breakthroughs have been made in immune diseases, although the vast majority of compound research is still in the preclinical stage. For example, fingolimod (FTY720; trade name Gilenya) was approved in 2010 by the American Food and Drugs Administration for the treatment of multiple sclerosis [52, 53]. This compound is an S1P agonist that binds to S1PR1, -3, -4, and -5 to stimulate their internalization and degradation, leading to their downregulation. In addition, it can directly inhibit SphK1 activity. Although it has been used clinically, its efficacy is poor. A randomized, double-blind, placebo-controlled trial of oral fingolimod in primary progressive multiple sclerosis indicated that fingolimod, despite its anti-inflammatory activity, failed to slow the progression of primary progressive multiple sclerosis [54]. Shortly afterward, Chitnis et al. [55] proposed that longer studies be performed to elucidate fingolimod safety and durability in pediatric patients with multiple sclerosis. In contrast, fingolimod potently prevents the Ca2+ mobilization and migration induced by S1P in vascular endothelial cells and inhibits tumor vascularization and growth in some cancer models, such as Lewis lung carcinoma [56], colon cancer [57], hepatocellular carcinoma [58], and prostate cancer [59]. Furthermore, Beider et al. [60] identified cross-talk between the S1P and CXCR4 pathways in multiple myeloma cells. They subsequently demonstrated that fingolimod effectively reduced tumor burden in the bone marrow of multiple myeloma-bearing mice. Besides fingolimod, the remaining S1P agonists, such as siponimod, SEW2817, AUY954, ponesimod, and KRP-203, mainly target S1PR1, but their roles and mechanisms still need further study.

Table 1 The roles played by S1P agonists and antagonists
Full size table

As discussed above, and as an example of “functional antagonism”, binding of fingolimod to its receptors triggers their internalization and degradation. Therefore, S1P antagonists, by directly competing with S1P, are likely to obstruct downstream pathways. Evidence supporting this hypothesis was provided by knockdown of S1PR1 in T cells [61]. Unlike S1P agonists, antagonists of S1P can target different types of S1PRs. Murakami et al. [62] found that TY52156, as an antagonist of S1PR3, could directly inhibit S1P-mediated vascular contraction by activating calcium and Rho in vascular smooth muscle cells. JTE-013 is a controversial S1PR antagonist, with preclinical studies considering it an S1P2-selective antagonist [63]. However, recent studies suggested that submicromolar concentrations of JTE-013 antagonize S1P4, with higher concentrations affecting S1P3 [64, 65]. On the other hand, CYM-5478 appears to be a highly selective agonist of S1P2 [66]. Research work used CYM-5478 to establish in vitro and in vivo roles for S1P2, in cancer cells [67] and renal ischemia–reperfusion injury [68], respectively. Similarly, initial work has reported both an antagonist and an agonist that selectively act on S1P3. Collectively, these findings indicate the major advances in S1P antagonist development. Furthermore, compared with S1PR antagonist, these compounds remain to be examined in cancer models. Accordingly, further work is required to determine the antitumor properties of S1P antagonists.

Specific roles for the individual receptor subtypes in cancer

Most studies investigating the involvement of S1P signaling in cancer have typically relied on manipulating S1P metabolism or using nonselective receptor ligands. Nonetheless, genetic manipulation and correlation analyses have shed some light on the varied, and even conflicting, functions of different receptor subtypes. Briefly, the signaling pathways activated by S1P through S1PR1–5 signaling play specific roles in regulating the proliferation, migration, and/or invasion of cancer cells in a context-dependent manner (Fig. 2).

Fig. 2
figure 2

S1P receptor signaling. S1P exported to the extracellular space binds to the receptors and activates the receptor-bound G-proteins (Gi, Gq, G12/13). The activated G-proteins subsequently trigger the downstream pathways, which plays a role in growth, proliferation, migration and invasion of cancer

Full size image

The role of S1PR1 in cancer

S1PR1, when specifically bound to Gi, activates numerous signaling pathways, such as Ras/ERK, NLRP3/IL-1β, PI3K/AKT, PI3K/Rac, STAT3, and PLC, and is largely regarded as a protumorigenic factor, promoting migration, invasion, proliferation, and neovascularization in various kinds of cancer [69]. RNA interference experiments have shown that S1PR1 is required in vivo for tumor angiogenesis [70]. In breast cancer, the SphK1/S1P/S1PR1 axis is critically involved in regulating numerous cellular processes, including cell growth, survival, invasion, vascular integrity, immune cell trafficking, angiogenesis, and cytokine and chemokine production [19, 21, 71,72,73]. Therefore, the question is whether we can decrease tumor viability and growth by inhibiting S1PR1 expression. The answer is, unfortunately, no. Liu et al. [74] showed that S1PR1 can accelerate VE-cadherin phosphorylation (Y731) by activating RhoA, leading to increased endothelium-dependent vessel and reduced vasculogenic mimicry in breast cancer, and the low expression of S1PR1 is in line with the vasculogenic mimicry and poor prognosis in breast cancer patients. In the mouse B16 tumor model, activated S1PR1 can accelerate tumor progression by activating STAT3 and upregulating IL-6 [75], and this relationship between S1PR1 and STAT3 has been shown to contribute to chronic intestinal inflammation and colitis-associated colon cancer [57]. In Wilms tumor (also called nephroblastoma), S1PR1 stimulates migration and invasion through PI3K and the Rac pathway, which has promigratory properties [76]. S1PR1 overexpression, which contributes to the expression and activity of urokinase plasminogen activator (uPA), significantly expedites invasion in glioblastoma [77]. In addition, S1PR1 can also activate ERK to enhance cell survival [78] and promote cell migration in fibrosarcoma [79] and Hodgkin lymphoma [80]. A recent study illustrated that the microRNA302-367-ERK1/2-KLF2-S1PR1 pathway can restrict angiogenesis and stabilize vascular cells, which means that the ERK1/2-KLF2-S1PR1 pathway may promote tumor growth by stimulating angiogenesis [81].

The role of S1PR2 in cancer

S1PR2, in contrast to S1PR1, can bind to multiple Gα proteins, including Gi, G12/13, and Gq. Therefore, S1PR2 can play multiple functions in the progression of cancer by affecting a diverse range of downstream second messengers.

The protumorigenic potential of S1P2 activation has been indicated in some recent studies. Cholangiocarcinoma has been closely linked to chronic cholestasis and significantly increased levels of bile acids, both primary and conjugated. Liu et al. [82] suggested that conjugated bile acids can activate ERK1/-2 and AKT signaling pathways through S1PR2 in rodent hepatocytes. Furthermore, their subsequent findings indicated that S1PR2 is vital for conjugated bile acid-mediated cholangiocarcinoma cell growth and invasion. In Wilms tumor, S1PR2 was found to contribute to tumor growth and angiogenesis by stimulating the expression of cyclooxygenase 2 (COX-2) [11]. In glioma cells, Young and Van Brocklyn [83] found that overexpression of S1PR2 significantly increased the invasiveness of U-118 MG cells, despite decreasing cell motility. A more detailed study, which included in vivo and in vitro experiments related to pancreatic cancer, demonstrated that S1P activates pancreatic stellate cells to produce matrix metalloproteinase-9 (MMP-9) through an S1P2-, c-Abl-, and NF-κB-dependent pathway. This series of reactions ultimately stimulates pancreatic cancer cell migration and invasion [84]. An in vivo allograft study revealed that communication from SphK/S1P signaling of host cells with S1P2 expressed by allografted bladder cancer cells facilitates lung cancer metastasis [85]. In hepatocellular carcinoma, Cheng et al. [86] showed that S1P plays a role in stimulating hepatocellular carcinoma cell proliferation by upregulating connective tissue growth factor (CTGF) expression through S1P2-mediated Yes-associated protein (YAP) activation. Besides its tumorigenicity, S1PR2 may increase resistance to imatinib and nilotinib in chronic myeloid leukemia patients by inhibiting the activity of protein phosphatase 2A and thereby stabilizing Bcr-Abl1 protein [87]. In addition, non-neoplastic work has shown that activation of S1P2 can increase cell viability and reduce cisplatin-mediated cell death by decreasing reactive oxygen species (ROS) [66].

Surprisingly, S1PR2 also plays an important role in suppressing cancer. S1PR1–5 and S1P metabolic enzymes are found in three different human glioblastoma cell lines and S1P has wide-ranging effects on glioblastoma cell migration [88]. Moreover, Lepley et al. [89], after using FTY720-P, one of the S1P analogues, to bind all S1P receptors except S1PR2, found that migration was not suppressed. However, overexpression of S1P2 inhibited migration, and their further work illustrated that S1P2 has a suppressive effect on glioblastoma cell migration, although this did not correlate with proliferation. In thyroid cancer, Asghar et al. [90] demonstrated that S1P inhibits the invasive properties of C643 thyroid cancer cells by activating S1P2 and the Rho-ROCK pathway. In Wilms tumor, the effect of S1PR2 is different from that discussed above, and S1PR2 appears to stimulate the Rho/Rho kinase/JNK pathway and thereby block cell proliferation by inducing the immediate expression of CTGF [12]. Moreover, some studies indirectly illustrated the antitumorigenic activity of S1PR2. For example, disruption of the gene expression of S1P receptors for S1P2 leads to diffuse large B-cell lymphoma (DLBCL) formation in S1P2 knockout mice [91]. Similarly, Stelling et al. [92] manifested the suppressive function of the TGF-β/TGF-βR2/SMAD1/S1PR2 axis in DLBCL and showed that DLBCL cells have evolved to be able to inactivate the pathway at the SMAD1 expression level. The 14-3-3ζ protein may promote the invasion of esophageal squamous cell carcinoma by repressing S1PR2 expression through NF-κB signaling [93].

The role of S1PR3 in cancer

S1PR3, coupled to Gi, Gq, and G12/13, has a close correspondence with human breast cancer. Not only is it the most highly expressed S1PR in human breast cancer cell lines [94], but also its activation may promote tumor progression and reduce overall survival in patients with breast cancer [95,96,97]. Consistently associated with Epstein-Barr virus infection, the pathogenesis of nasopharyngeal carcinoma has also recently been linked to S1P/S1PR3 signaling. S1PR3 mRNA is overexpressed in Epstein–Barr virus-positive nasopharyngeal carcinoma patient-derived xenografts and some primary nasopharyngeal carcinoma tissues and its knockdown blocks both AKT activation and the migration of nasopharyngeal carcinoma cells induced by S1P [98]. Because S1PR3 levels are elevated in a series of human lung adenocarcinoma cell lines, Zhao et al. [99] found that TGF-β-stimulated S1PR3 upregulation boosts the proliferation of human lung adenocarcinoma cells in mice through the TGF-β/SMAD3 pathway; in contrast, knockdown of S1PR3 markedly blocks tumor growth and lung metastasis. Earlier studies showed that S1P/S1PR3 signaling increases the expression of endothelial growth factor receptors (EGFR) in lung adenocarcinoma cells through the Rho kinase pathway and enhances EGF-stimulated cell proliferation, cell invasion, and colony formation [100]. Like S1P1, S1P3 contributes to angiogenesis, although less strongly [101]. The S1P/S1PR3 axis is involved in promoting proliferation, inhibiting apoptosis, and accelerating aerobic glycolysis in osteosarcoma cells via the YAP/c-MYC/PGAM1 pathway [102].

The role of S1PR4 and S1PR5 in cancer

Compared with S1PR1–3, S1PR4 and S1PR5 have a restricted distribution and less clear functions. Current research indicates that S1PR4 and S1PR5 couple to Gi and G12/13 [103, 104]. In breast cancer, S1P/S1PR4 signaling can activate the Erk1/2 and human epidermal growth factor receptor-2 (HER2) pathways and increase tumor aggressiveness [105, 106]. It is also correlated with worse outcomes and shorter survival in estrogen receptor-negative breast cancer [105]. Moreover, by activating S1PR4 signaling, SPHK2-generated S1P prevents the nuclear translocation of S1PR2 and boosts the proliferation of estrogen receptor-negative breast cancer cells [107]. Nonetheless, further work is required to clarify how S1PR4 regulates the nuclear translocation of S1PR2, as well as how nuclear S1PR2 inhibits the growth of estrogen receptor-negative breast cancer cells. S1P5 boosts survival in prostate cancer by inducing autophagy under serum-deprived conditions [108]. However, S1P5 is expressed at a lower level in esophageal squamous cell carcinoma than in normal esophageal mucosal epithelium [109]. In addition, S1PR4 and S1PR5 play important roles in inflammation, which is also closely related to the progression of some cancers, such as colon cancer [110].

The therapeutic potential of S1P signaling in cancer

As reviewed here, numerous studies have demonstrated that S1P signaling is closely associated with cancer progression. Moreover, growing evidence indicates S1P signaling as a potential therapeutic target. Thus far, focusing on S1P signaling as a promising therapeutic target, there are two main research strategies: one is to reduce the levels of S1P itself, the other is to agonize/antagonize S1P receptors. Two drug candidates have been clinically used to reduce S1P levels in the oncology field. A phase II trial of the first, LT1002/sonepcizumab, which can selectively bind S1P with picomolar affinity and block S1P-induced cytokine release, was terminated due to a lack of efficacy [111]. The second, ABC294640, a selective SphK2 inhibitor, effectively reduced the levels of S1P and inhibited the growth of multiple cancers in vitro and in preclinical xenograft studies [112,113,114]. This inhibitor is now being studied in a phase I/II clinical trial for DLBCL; the final results are not yet available. In addition, considerable progress has made in preclinical studies focusing on SphK inhibitors (SKIs). Two such SKIs are SKI-I (4-(4′-phenoxyanilino)-6,7-dimethoxyquinazoline) and SKI-II (4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol) [115, 116]. By inhibiting SphK activity, these small-molecule compounds reduce S1P levels. The first, SKI-I, is a slightly stronger inhibitor of SPHK1 versus SPHK2 [117] and blocks SPHK1 activity in vitro to decrease JC mammary tumor growth [115]. In mice, by arresting cells in the G2/M and S cell cycle phases and by increasing cell apoptosis, intraperitoneal SKI-I decreases melanoma tumor growth [118]. SKI-II has worse SphK1/SphK2 selectivity compared with SKI-I, although it has been applied extensively in biological investigations of the role of SphK1 and SphK2 in disease and has exhibited impressive anticancer effects [119]. Yang et al. [120] demonstrated that SKI-II more efficiently suppresses the proliferation and survival of two human acute myeloid leukemia cell lines—HL-60 and U937 cells—than two other SphK1 inhibitors (fingolimod and SK1-I). Another study found that SKI-II suppresses the growth of human hepatoma HepG2 cells by decreasing the expression of β-catenin and the downstream molecules in the β-catenin signaling pathway [121]. In addition, SKI-II can also increase the sensitivity of hepatocellular carcinoma cells to the chemotherapeutic drug 5-fluorouracil by inhibiting FAK/IGF-1R and osteopontin signaling [122].

S1P exerts pleiotropic bioactive effects through the S1PRs (S1PR1–5). The roles played by these receptors in cancer are increasingly better understood. Accordingly, one possible cancer therapeutic approach with considerable potential would be to selectively target these receptors with agonists or antagonists. Recently, numerous studies have illustrated the validity of the strategy [67, 93, 123]. As far as S1PR2 is concerned, S1PR2 signaling induces acute myeloid leukemia growth or proliferation [124] and mediates tumor metastasis in bladder cancer and melanoma cells [85]. In addition, S1PR2 can also inhibit tumor angiogenesis in mouse models [125], due to its dual nature in the pathogenesis of cancer. Thus, these data suggest that selective targeting of S1PR2 in cancer cells, at least in acute myeloid leukemia, bladder cancer, and melanoma, may provide an anticancer therapeutic strategy. Unfortunately, however, fingolimod is the only S1PR-related drug used in clinical practice, mainly to treat multiple sclerosis. The reason is that five different S1PR each other and nonselective drug greatly reduce anticancer effect. Furthermore, these wide-ranging anticancer actions may interfere with a number of unrelated signaling pathways, such as SET/PP2A and PI3K/AKT [123] (Table 2).

Table 2 Roles played by individual S1PRs in different cancer
Full size table

Therefore, a long and arduous road remains, although S1P signaling is nonetheless a promising therapeutic target in cancer. First of all, further research is needed to obtain more detailed information on the S1P signaling pathway. In addition, the development is required of more effective and specific modulators of the various S1P signaling pathway components to maximize therapeutic efficacy and minimize adverse effects such as cytotoxicity.

Conclusion

In the past two decades, considerable effort has been expended in clarifying the function of S1P signaling in the progression and treatment of cancer, as well as in exploring S1P signaling modulators, such as SphK, S1P transporters and receptors, and S1P agonists and antagonists. S1P and its signaling cascades are strongly linked to numerous aspects of cancer progression, including cell survival, proliferation, and migration, as well as chemotherapy resistance. Given this seemingly hopeless situation, with no effective methods to combat the all-too-often devastating effects of cancer, there is no doubt that further research is warranted to develop targeted therapies. In terms of the existing study results, S1P signaling is likely to be a much-needed novel target for the treatment of cancer. While meeting the opportunity, we should also be prepared to face enormous challenges. (1) Current research results indicate that S1PR1 and S1PR3, which have many similar aspects, both play roles in promoting the occurrence and development of tumors. Therefore, the targeting of S1P1 and S1PR3 may have great therapeutic potential for cancer. However, because the therapeutic efficacy of suppression or gene knockout of S1PR1 or S1PR3 varies widely for different types of tumors (currently only in tumor models or cells), further preclinical and even clinical trials are necessary. (2) S1PR2 is a double-edged sword, which has the dual role of promoting cancer and inhibiting cancer. Most of the existing studies only indicate the role of S1PR2 in certain tumors, and the next breakthrough involving S1PR2 will probably rely on actively exploring this dual-effect mechanism in order to reduce or remove the cancer-promoting effect and/or improve the anti-cancer effect. (3) Compared with S1PR1–3, S1PR4 and S1PR5 have a restricted distribution and less clear functions, and further research is needed to obtain more detailed information on S1P4 and S1PR5. In addition, there are close and complex interactions among S1P, SphK, S1P transporter, its degrading enzymes, and S1PR1–5, and they all play important roles in cancer, inflammation, immune, and angiogenesis. Elucidation of these complex interactions may be one of the most demanding future challenges. In addition, recent efforts have produced a variety of S1P agonists/antagonists that target different S1PRs, some of which have been shown to have major roles in cancer. For instance, FTY720, an S1P agonist that binds to S1PR1, S1PR3, S1PR4, and S1PR5, has been indicated to suppress the growth and aggressiveness of tumor in several cancer models. In addition, an S1P antagonist, CYM-5478, may promote tumor aggressiveness by targeting S1PR2 in oral squamous cell carcinoma. However, other S1P agonists and antagonists have not been researched or tested in cancer models. Therefore, more studies are needed to evaluate the effects of these S1P agonists/antagonists in cancer. With the increased focus on S1P agonists/antagonists in cancer and the resultant progress, S1P agonists/antagonists might become a promising therapy for cancer patients.

Availability of data and materials

Not applicable.

Abbreviations

S1P:

sphingosine-1-phosphate

SphKs:

sphingosine kinases

ABCC1:

ATP-binding cassette C1

ABCG2:

ATP-binding cassette G2

Spns2:

spinster 2

S1PRs:

S1P receptors

Gq, Gi, and G12/13:

G protein α subtypes

AKT:

protein kinase B

ERK1/2:

extracellular regulated protein kinases

SphK1:

sphingosine kinase 1

SphK2:

sphingosine kinase 2

GPCRs:

G protein-coupled receptors

LPA:

lysophosphatidic acid

CXCR4:

chemokine receptor type 4

Ras:

rat sarcoma viral oncogene

ERK:

extracellular regulated protein kinases

NLRP3:

NACHT, LRR and PYD domains-containing protein 3

IL-1β:

interleukin-1β

PI3K:

phosphoinositide 3-kinase

STAT3:

signal transducer and activator of transcription 3

PLC:

phospholipases C

uPA:

urokinase plasminogen activator

KLF2:

Krüppel-like factor 2

COX-2:

cyclooxygenase 2

MMP-9:

matrix metalloproteinase-9

NF-κB:

nuclear factor kappa-light-chain-enhancer of activated B cells

CTGF:

connective tissue growth factor

YAP:

Yes-associated protein

ROS:

reactive oxygen species

ROCK:

Rho-associated kinase

JNK:

c-Jun N-terminal kinases

DLBCL:

diffuse large B cell lymphoma

TGF-β:

transforming growth factor beta

TGF-βR2:

transforming growth factor β receptor 2

SMAD1:

Mothers against decapentaplegic homolog 1

SMAD3:

Mothers against decapentaplegic homolog 3

EGFR:

endothelial growth factor receptors

EGF:

epidermal growth factor

c-MYC:

cellular-myelocytomatosis viral oncogene

PGAM1:

phosphoglycerate mutase 1

HER2:

human epidermal growth factor receptor-2

SKIs:

SphK inhibitors

PP2A:

protein phosphatase 2

SET:

patient se translocation

References

  1. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J Cell Biochem. 2004;92(5):882–99.

    Article  PubMed  CAS  Google Scholar 

  2. Takabe K, Kim RH, Allegood JC, Mitra P, Ramachandran S, Nagahashi M, et al. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J Biol Chem. 2010;285(14):10477–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Nagahashi M, Kim EY, Yamada A, Ramachandran S, Allegood JC, Hait NC, et al. Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network. FASEB J. 2013;27(3):1001–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Nagahashi M, Takabe K, Terracina KP, Soma D, Hirose Y, Kobayashi T, et al. Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed Res Int. 2014;2014:651727.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007;115(1):84–105.

    Article  CAS  PubMed  Google Scholar 

  6. Takashima S, Sugimoto N, Takuwa N, Okamoto Y, Yoshioka K, Takamura M, et al. G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc Res. 2008;79(4):689–97.

    Article  CAS  PubMed  Google Scholar 

  7. Xiao SJ, Yang J. Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR(1)-antibody) against human breast cancer cells. Invest New Drug. 2019;37(1):57–64.

    Article  CAS  Google Scholar 

  8. Koch A, Pfeilschifter J, Huwiler A. Sphingosine 1-phosphate in renal diseases. Cell Physiol Biochem. 2013;31(6):745–60.

    Article  CAS  PubMed  Google Scholar 

  9. Mao-Draayer Y, Sarazin J, Fox D, Schiopu E. The sphingosine-1-phosphate receptor: a novel therapeutic target for multiple sclerosis and other autoimmune diseases. Clin Immunol. 2017;175:10–5.

    Article  CAS  PubMed  Google Scholar 

  10. Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50.

    Article  CAS  PubMed  Google Scholar 

  11. Li MH, Sanchez T, Milne GL, Morrow JD, Hla T, Ferrer F. S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor. J Urol. 2009;181(3):1347–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Li MH, Sanchez T, Pappalardo A, Lynch KR, Hla T, Ferrer F. Induction of antiproliferative connective tissue growth factor expression in Wilms’ tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res. 2008;6(10):1649–56.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.

    Article  CAS  PubMed  Google Scholar 

  14. Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101.e5–2114.e5.

    Article  CAS  Google Scholar 

  15. Takabe K, Paugh SW, Milstien S, Spiegel S. “Inside-out” signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev. 2008;60(2):181–95.

    Article  CAS  PubMed  Google Scholar 

  16. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397–407.

    Article  CAS  PubMed  Google Scholar 

  17. Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R, et al. SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem. 2005;280(44):37118–29.

    Article  CAS  PubMed  Google Scholar 

  18. Fang H, Declerck YA. Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res. 2013;73(16):4965–77.

    Article  CAS  PubMed  Google Scholar 

  19. Takabe K, Spiegel S. Export of sphingosine-1-phosphate and cancer progression. J Lipid Res. 2014;55(9):1839–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nagahashi M, Yamada A, Katsuta E, Aoyagi T, Huang WC, Terracina KP, et al. Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis. Cancer Res. 2018;78(7):1713–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Nagahashi M, Ramachandran S, Kim EY, Allegood JC, Rashid OM, Yamada A, et al. Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis. Cancer Res. 2012;72(3):726–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Hanyu T, Nagahashi M, Ichikawa H, Ishikawa T, Kobayashi T, Wakai T. Expression of phosphorylated sphingosine kinase 1 is associated with diffuse type and lymphatic invasion in human gastric cancer. Surgery. 2018;163(6):1301–6.

    Article  PubMed  Google Scholar 

  23. Yuza K, Nakajima M, Nagahashi M, Tsuchida J, Hirose Y, Miura K, et al. Different roles of sphingosine kinase 1 and 2 in pancreatic cancer progression. J Surg Res. 2018;232:186–94.

    Article  CAS  PubMed  Google Scholar 

  24. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science. 2009;325(5945):1254–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature. 2010;465(7301):1084.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hait NC, Wise LE, Allegood JC, O’Brien M, Avni D, Reeves TM, et al. Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Nat Neurosci. 2014;17(7):971–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Nagahashi M, Takabe K, Liu RP, Peng KS, Wang X, Wang Y, et al. Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology. 2015;61(4):1216–26.

    Article  CAS  PubMed  Google Scholar 

  28. Olivera A, Mizugishi K, Tikhonova A, Ciaccia L, Odom S, Proia RL, et al. The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity. 2007;26(3):287–97.

    Article  CAS  PubMed  Google Scholar 

  29. Samy ET, Meyer CA, Caplazi P, Langrish CL, Lora JM, Bluethmann H, et al. Cutting edge: modulation of intestinal autoimmunity and IL-2 signaling by sphingosine kinase 2 independent of sphingosine 1-phosphate. J Immunol. 2007;179(9):5644–8.

    Article  CAS  PubMed  Google Scholar 

  30. Jin L, Liu WR, Tian MX, Fan J, Shi YH. The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. World J Surg Oncol. 2016;14:131.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, Spiegel S. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci USA. 2006;103(44):16394–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lee YM, Venkataraman K, Hwang SI, Han DK, Hla T. A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat. 2007;84(3–4):154–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Osborne N, Brand-Arzamendi K, Ober EA, Jin SW, Verkade H, Holtzman NG, et al. The spinster homolog, two of hearts, is required for sphingosine 1-phosphate signaling in zebrafish. Curr Biol. 2008;18(23):1882–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Gaengel K, Niaudet C, Hagikura K, Laviña B, Siemsen BL, Muhl L, et al. The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2. Dev Cell. 2012;23(3):587–99.

    Article  CAS  PubMed  Google Scholar 

  35. Mendelson K, Zygmunt T, Torres-Vazquez J, Evans T, Hla T. Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning. J Biol Chem. 2013;288(4):2143–56.

    Article  CAS  PubMed  Google Scholar 

  36. Kawahara A, Nishi T, Hisano Y, Fukui H, Yamaguchi A, Mochizuki N. The sphingolipid transporter spns2 functions in migration of zebrafish myocardial precursors. Science. 2009;323(5913):524–7.

    Article  CAS  PubMed  Google Scholar 

  37. Nagahashi M, Yamada A, Aoyagi T, Allegood J, Wakai T, Spiegel S, et al. Sphingosine-1-phosphate in the lymphatic fluid determined by novel methods. Heliyon. 2016;2(12):e00219.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Nagahashi M, Abe M, Sakimura K, Takabe K, Wakai T. The role of sphingosine-1-phosphate in inflammation and cancer progression. Cancer Sci. 2018;109(12):3671–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kumar A, Zamora-Pineda J, Degagne E, Saba JD. S1P lyase regulation of thymic egress and oncogenic inflammatory signaling. Mediators Inflamm. 2017;2017:7685142.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Schwiebs A, San Juan MH, Schmidt KG, Wiercinska E, Anlauf M, Ottenlinger F, et al. Cancer-induced inflammation and inflammation-induced cancer in colon: a role for S1P lyase. Oncogene. 2019;38(24):4788.

    Article  CAS  PubMed  Google Scholar 

  41. Oskouian B, Sooriyakumaran P, Borowsky AD, Crans A, Dillard-Telm L, Tam YY, et al. Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci USA. 2006;103(46):17384–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Moro K, Kawaguchi T, Tsuchida J, Gabriel E, Qi Q, Yan L, et al. Ceramide species are elevated in human breast cancer and are associated with less aggressiveness. Oncotarget. 2018;9(28):19874–90.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, et al. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Investig. 2001;108(5):689–701.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kendall AC, Nicolaou A. Bioactive lipid mediators in skin inflammation and immunity. Prog Lipid Res. 2013;52(1):141–64.

    Article  CAS  PubMed  Google Scholar 

  45. Kihara Y, Maceyka M, Spiegel S, Chun J. Lysophospholipid receptor nomenclature review: IUPHAR Review 8. Br J Pharmacol. 2014;171(15):3575–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998;279(5356):1552–5.

    Article  CAS  PubMed  Google Scholar 

  47. Nakajima M, Nagahashi M, Tsuchida J, Ichikawa H, Shimada Y, Wakai T. Function analysis of sphingosine-1-phosphate produced by sphingosine kinases in pancreatic cancer progression. Cancer Sci. 2018;109:967.

    Article  CAS  Google Scholar 

  48. Zhou YJ, Guo F. A selective sphingosine-1-phosphate receptor 1 agonist SEW-2871 aggravates gastric cancer by recruiting myeloid-derived suppressor cells. J Biochem. 2018;163(1):77–83.

    Article  CAS  PubMed  Google Scholar 

  49. Zheng XJ, Li W, Ren LW, Liu JY, Pang XC, Chen XP, et al. The sphingosine kinase-1/sphingosine-1-phosphate axis in cancer: potential target for anticancer therapy. Pharmacol Ther. 2019;195:85–99.

    Article  CAS  PubMed  Google Scholar 

  50. Ng ML, Wadham C, Sukocheva OA. The role of sphingolipid signalling in diabetesassociated pathologies (review). Int J Mol Med. 2017;39(2):243–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Chew WS, Wang W, Herr DR. To fingolimod and beyond: the rich pipeline of drug candidates that target S1P signaling. Pharmacol Res. 2016;113(Pt A):521–32.

    Article  CAS  PubMed  Google Scholar 

  52. Jesko H, Wencel PL, Lukiw WJ, Strosznajder RP. Modulatory effects of fingolimod (FTY720) on the expression of sphingolipid metabolism-related genes in an animal model of Alzheimer’s disease. Mol Neurobiol. 2019;56(1):174–85.

    Article  CAS  PubMed  Google Scholar 

  53. Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759–77.

    Article  CAS  PubMed  Google Scholar 

  54. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–84.

    Article  CAS  PubMed  Google Scholar 

  55. Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N Engl J Med. 2018;379(11):1017–27.

    Article  CAS  PubMed  Google Scholar 

  56. Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, et al. The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. J Cell Biochem. 2007;101(1):259–70.

    Article  CAS  PubMed  Google Scholar 

  57. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang WC, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23(1):107–20.

    Article  CAS  PubMed  Google Scholar 

  58. Hung JH, Lu YS, Wang YC, Ma YH, Wang DS, Kulp SK, et al. FTY720 induces apoptosis in hepatocellular carcinoma cells through activation of protein kinase C delta signaling. Can Res. 2008;68(4):1204–12.

    Article  CAS  Google Scholar 

  59. Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70(21):8651–61.

    Article  CAS  PubMed  Google Scholar 

  60. Beider K, Rosenberg E, Bitner H, Shimoni A, Leiba M, Koren-Michowitz M, et al. The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4/CXCL12 pathway. Clin Cancer Res. 2017;23(7):1733–47.

    Article  CAS  PubMed  Google Scholar 

  61. Allende ML, Proia RL. Sphingosine-1-phosphate receptors and the development of the vascular system. BBA-Mol Cell Biol Lipid. 2002;1582(1–3):222–7.

    Article  CAS  Google Scholar 

  62. Murakami A, Takasugi H, Ohnuma S, Koide Y, Sakurai A, Takeda S, et al. Sphingosine 1-phosphate (S1P) regulates vascular contraction via S1P3 receptor: investigation based on a new S1P3 receptor antagonist. Mol Pharmacol. 2010;77(4):704–13.

    Article  CAS  PubMed  Google Scholar 

  63. Yamamoto S, Yako Y, Fujioka Y, Kajita M, Kameyama T, Kon S, et al. A role of the sphingosine-1-phosphate (S1P)-S1P receptor 2 pathway in epithelial defense against cancer (EDAC). Mol Biol Cell. 2016;27(3):491–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Long JS, Fujiwara Y, Edwards J, Tannahill CL, Tigyi G, Pyne S, et al. Sphingosine 1-phosphate receptor 4 uses HER2 (ERBB2) to regulate extracellular signal regulated kinase-1/2 in MDA-MB-453 breast cancer cells. J Biol Chem. 2010;285(46):35957–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Salomone S, Waeber C. Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects. Front Pharmacol. 2011;2:9.

    PubMed  PubMed Central  Google Scholar 

  66. Herr DR, Reolo MJ, Peh YX, Wang W, Lee CW, Rivera R, et al. Sphingosine 1-phosphate receptor 2 (S1P2) attenuates reactive oxygen species formation and inhibits cell death: implications for otoprotective therapy. Sci Rep. 2016;6:24541.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Patmanathan SN, Johnson SP, Lai SL, Panja Bernam S, Lopes V, Wei W, et al. Aberrant expression of the S1P regulating enzymes, SPHK1 and SGPL1, contributes to a migratory phenotype in OSCC mediated through S1PR2. Sci Rep. 2016;6:25650.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Park SW, Kim M, Brown KM, D’Agati VD, Lee HT. Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury. J Am Soc Nephrol. 2012;23(2):266–80.

    Article  CAS  PubMed  Google Scholar 

  69. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 2008;9(8):662–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Chae SS, Paik JH, Furneaux H, Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest. 2004;114(8):1082–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Nagahashi M, Yamada A, Katsuta E, Aoyagi T, Huang WC, Terracina KP, et al. Targeting the SphK1/S1P/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis. Can Res. 2018;78(7):1713–25.

    Article  CAS  Google Scholar 

  72. Nagahashi M, Yuza K, Hirose Y, Nakajima M, Ramanathan R, Hait NC, et al. The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. J Lipid Res. 2016;57(9):1636–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Weichand B, Popp R, Dziumbla S, Mora J, Strack E, Elwakeel E, et al. S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1β. J Exp Med. 2017;214(9):2695–713.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Liu S, Ni C, Zhang D, Sun H, Dong X, Che N, et al. S1PR1 regulates the switch of two angiogenic modes by VE-cadherin phosphorylation in breast cancer. Cell Death Dis. 2019;10(3):200.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Lee H, Deng J, Kujawski M, Yang C, Liu Y, Herrmann A, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16(12):1421–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Li MH, Sanchez T, Yamase H, Hla T, Oo ML, Pappalardo A, et al. S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett. 2009;276(2):171–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Young N, Pearl DK, Van Brocklyn JR. Sphingosine-1-phosphate regulates glioblastoma cell invasiveness through the urokinase plasminogen activator system and CCN1/Cyr61. Mol Cancer Res. 2009;7(1):23–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Rutherford C, Childs S, Ohotski J, McGlynn L, Riddick M, MacFarlane S, et al. Regulation of cell survival by sphingosine-1-phosphate receptor S1P1 via reciprocal ERK-dependent suppression of Bim and PI-3-kinase/protein kinase C-mediated upregulation of Mcl-1. Cell Death Dis. 2013;4:e927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Fisher KE, Pop A, Koh W, Anthis NJ, Saunders WB, Davis GE. Tumor cell invasion of collagen matrices requires coordinate lipid agonist-induced G-protein and membrane-type matrix metalloproteinase-1-dependent signaling. Mol Cancer. 2006;5:69.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Kluk MJ, Ryan KP, Wang B, Zhang G, Rodig SJ, Sanchez T. Sphingosine-1-phosphate receptor 1 in classical Hodgkin lymphoma: assessment of expression and role in cell migration. Lab Invest. 2013;93(4):462–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Pi J, Tao T, Zhuang T, Sun H, Chen X, Liu J, et al. A MicroRNA302-367-Erk1/2-Klf2-S1pr1 pathway prevents tumor growth via restricting angiogenesis and improving vascular stability. Circ Res. 2017;120(1):85–98.

    Article  CAS  PubMed  Google Scholar 

  82. Liu R, Zhao R, Zhou X, Liang X, Campbell DJ, Zhang X, et al. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2. Hepatology. 2014;60(3):908–18.

    Article  CAS  PubMed  Google Scholar 

  83. Young N, Van Brocklyn JR. Roles of sphingosine-1-phosphate (S1P) receptors in malignant behavior of glioma cells. Differential effects of S1P2 on cell migration and invasiveness. Exp Cell Res. 2007;313(8):1615–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Bi Y, Li J, Ji B, Kang N, Yang L, Simonetto DA, et al. Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth. Am J Pathol. 2014;184(10):2791–802.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Ponnusamy S, Selvam SP, Mehrotra S, Kawamori T, Snider AJ, Obeid LM, et al. Communication between host organism and cancer cells is transduced by systemic sphingosine kinase 1/sphingosine 1-phosphate signalling to regulate tumour metastasis. Embo Mol Med. 2012;4(8):761–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Cheng JC, Wang EY, Yi Y, Thakur A, Tsai SH, Hoodless PA. S1P stimulates proliferation by upregulating CTGF expression through S1PR2-mediated YAP activation. Mol Cancer Res. 2018;16(10):1543–55.

    Article  CAS  PubMed  Google Scholar 

  87. Salas A, Ponnusamy S, Senkal CE, Meyers-Needham M, Selvam SP, Saddoughi SA, et al. Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A. Blood. 2011;117(22):5941–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Van Brocklyn J, Letterle C, Snyder P, Prior T. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Lett. 2002;181(2):195–204.

    Article  PubMed  Google Scholar 

  89. Lepley D, Paik JH, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Can Res. 2005;65(9):3788–95.

    Article  CAS  Google Scholar 

  90. Asghar MY, Kemppainen K, Lassila T, Tornquist K. Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: importance of S1P2. PLoS ONE. 2018;13(5):e0196992.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Can Res. 2009;69(22):8686–92.

    Article  CAS  Google Scholar 

  92. Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, Müller A. The tumor suppressive TGF-β/SMAD1/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood. 2018;131(20):2235–46.

    Article  CAS  PubMed  Google Scholar 

  93. Tong S, Chen SC, Xu KY, Fang B, Wang SH, Wang JJ. 14-3-3ζ promotes esophageal squamous cell carcinoma invasion by repressing S1PR2 protein expression through NF-κB signaling. Arch Biochem Biophys. 2018;643:7–13.

    Article  CAS  PubMed  Google Scholar 

  94. Goetzl EJ, Dolezalova H, Kong Y, Zeng L. Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells. Can Res. 1999;59(18):4732–7.

    CAS  Google Scholar 

  95. Wang S, Liang Y, Chang W, Hu B, Zhang Y. Triple negative breast cancer depends on sphingosine kinase 1 (SphK1)/sphingosine-1-phosphate (S1P)/sphingosine 1-phosphate receptor 3 (S1PR3)/Notch signaling for metastasis. Med Sci Monit. 2018;24:1912–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Watson C, Long JS, Orange C, Tannahill CL, Mallon E, McGlynn LM, et al. High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients. Am J Pathol. 2010;177(5):2205–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Hirata N, Yamada S, Shoda T, Kurihara M, Sekino Y, Kanda Y. Sphingosine-1-phosphate promotes expansion of cancer stem cells via S1PR3 by a ligand-independent Notch activation. Nat Commun. 2014;5:4806.

    Article  CAS  PubMed  Google Scholar 

  98. Lee HM, Lo KW, Wei W, Tsao SW, Chung GTY, Ibrahim MH, et al. Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3. J Pathol. 2017;242(1):62–72.

    Article  CAS  PubMed  Google Scholar 

  99. Zhao J, Liu J, Lee JF, Zhang W, Kandouz M, VanHecke GC, et al. TGF-β/SMAD3 pathway stimulates sphingosine-1 phosphate receptor 3 expression: implication of sphingosine-1 phosphate receptor 3 in lung adenocarcinoma progression. J Biol Chem. 2016;291(53):27343–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Hsu A, Zhang W, Lee JF, An J, Ekambaram P, Liu J, et al. Sphingosine-1-phosphate receptor-3 signaling up-regulates epidermal growth factor receptor and enhances epidermal growth factor receptor-mediated carcinogenic activities in cultured lung adenocarcinoma cells. Int J Oncol. 2012;40(5):1619–26.

    CAS  PubMed  Google Scholar 

  101. Lee MJ, Thangada S, Claffey KP, Ancellin N, Liu CH, Kluk M, et al. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999;99(3):301–12.

    Article  CAS  PubMed  Google Scholar 

  102. Shen Y, Zhao S, Wang S, Pan X, Zhang Y, Xu J, et al. S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma. EBioMedicine. 2019;40:210–23.

    Article  PubMed  Google Scholar 

  103. Gräler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J Cell Biochem. 2003;89(3):507–19.

    Article  PubMed  CAS  Google Scholar 

  104. Patmanathan SN, Wang W, Yap LF, Herr DR, Paterson IC. Mechanisms of sphingosine 1-phosphate receptor signalling in cancer. Cell Signal. 2017;34:66–75.

    Article  CAS  PubMed  Google Scholar 

  105. Ohotski J, Long JS, Orange C, Elsberger B, Mallon E, Doughty J, et al. Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer. Br J Cancer. 2012;106(8):1453–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Long JS, Edwards J, Watson C, Tovey S, Mair KM, Schiff R, et al. Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in estrogen receptor-positive breast cancer cells. Mol Cell Biol. 2010;30(15):3827–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Ohotski J, Rosen H, Bittman R, Pyne S, Pyne NJ. Sphingosine kinase 2 prevents the nuclear translocation of sphingosine 1-phosphate receptor-2 and tyrosine 416 phosphorylated c-Src and increases estrogen receptor negative MDA-MB-231 breast cancer cell growth: the role of sphingosine 1-phosphate receptor-4. Cell Signal. 2014;26(5):1040–7.

    Article  CAS  PubMed  Google Scholar 

  108. Chang CL, Ho MC, Lee PH, Hsu CY, Huang WP, Lee H. S1P(5) is required for sphingosine 1-phosphate-induced autophagy in human prostate cancer PC-3 cells. Am J Physiol Cell Physiol. 2009;297(2):C451–8.

    Article  CAS  PubMed  Google Scholar 

  109. Hu WM, Li L, Jing BQ, Zhao YS, Wang CL, Feng L, et al. Effect of S1P5 on proliferation and migration of human esophageal cancer cells. World J Gastroenterol. 2010;16(15):1859–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Aoki M, Aoki H, Ramanathan R, Hait NC, Takabe K. Sphingosine-1-phosphate signaling in immune cells and inflammation: roles and therapeutic potential. Mediators Inflamm. 2016;2016:8606878.

    PubMed  PubMed Central  Google Scholar 

  111. O’Brien N, Jones ST, Williams DG, Cunningham HB, Moreno K, Visentin B, et al. Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies. J Lipid Res. 2009;50(11):2245–57.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  112. French KJ, Zhuang Y, Maines LW, Gao P, Wang W, Beljanski V, et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther. 2010;333(1):129–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Zhou J, Chen J, Yu H. Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth. Biochem Biophys Res Commun. 2018;497(2):535–42.

    Article  CAS  PubMed  Google Scholar 

  114. Schrecengost RS, Keller SN, Schiewer MJ, Knudsen KE, Smith CD. Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression. Mol Cancer Res. 2015;13(12):1591–601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Can Res. 2003;63(18):5962–9.

    CAS  Google Scholar 

  116. French KJ, Upson JJ, Keller SN, Zhuang Y, Yun JK, Smith CD. Antitumor activity of sphingosine kinase inhibitors. J Pharmacol Exp Ther. 2006;318(2):596–603.

    Article  CAS  PubMed  Google Scholar 

  117. Hengst JA, Wang X, Sk UH, Sharma AK, Amin S, Yun JK. Development of a sphingosine kinase 1 specific small-molecule inhibitor. Bioorg Med Chem Lett. 2010;20(24):7498–502.

    Article  CAS  PubMed  Google Scholar 

  118. Madhunapantula SV, Hengst J, Gowda R, Fox TE, Yun JK, Robertson GP. Targeting sphingosine kinase-1 to inhibit melanoma. Pigment Cell Melanoma Res. 2012;25(2):259–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. Aurelio L, Scullino CV, Pitman MR, Sexton A, Oliver V, Davies L, et al. From sphingosine kinase to dihydroceramide desaturase: a structure–activity relationship (SAR) study of the enzyme inhibitory and anticancer activity of 4-((4-(4-chlorophenyl)thiazol-2-yl)amino)phenol (SKI-II). J Med Chem. 2016;59(3):965–84.

    Article  CAS  PubMed  Google Scholar 

  120. Yang L, Weng W, Sun ZX, Fu XJ, Ma J, Zhuang WF. SphK1 inhibitor II (SKI-II) inhibits acute myelogenous leukemia cell growth in vitro and in vivo. Biochem Biophys Res Commun. 2015;460(4):903–8.

    Article  CAS  PubMed  Google Scholar 

  121. Liu H, Zhang CX, Ma Y, He HW, Wang JP, Shao RG. SphK1 inhibitor SKI II inhibits the proliferation of human hepatoma HepG2 cells via the Wnt5A/β-catenin signaling pathway. Life Sci. 2016;151:23–9.

    Article  CAS  PubMed  Google Scholar 

  122. Grbčić P, Tomljanović I, Klobučar M, Kraljević Pavelić S, Lučin K, Sedić M. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling. Biochem Biophys Res Commun. 2017;487(4):782–8.

    Article  PubMed  CAS  Google Scholar 

  123. Patmanathan SN, Yap LF, Murray PG, Paterson IC. The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod. J Cell Mol Med. 2015;19(10):2329–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017;129(6):771–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Du W, Takuwa N, Yoshioka K, Okamoto Y, Gonda K, Sugihara K, et al. S1P(2), the G protein-coupled receptor for sphingosine-1-phosphate, negatively regulates tumor angiogenesis and tumor growth in vivo in mice. Can Res. 2010;70(2):772–81.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

The authors acknowledge financial support from National Natural Science Foundation of China (Nos. 81630053, 81873918), Construction Project of Liaoning Medical Imaging and Interventional Medical Engineering Research Center (Grant No. 18-006-9-01) and Science and Technology Plan of Shenyang (Grant Nos. 17-230-9-42, 18-014-4-28).

Author information

Authors and Affiliations

  1. Key Laboratory of Diagnostic Imaging and Interventional Radiology of Liaoning Province, Department of Radiology, The First Affiliated Hospital of China Medical University, Shenyang, 110001, Liaoning, China

    Peng Wang, Yonghui Yuan, Wenda Lin, Hongshan Zhong, Ke Xu & Xun Qi

  2. Research and Academic Department, Cancer Hospital of China Medical University Liaoning Cancer Hospital & Institute, Shenyang, 110042, Liaoning, China

    Yonghui Yuan

Authors
  1. Peng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yonghui Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wenda Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hongshan Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ke Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xun Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KX and XQ supervised the whole work and revised the manuscript, PW made literature search and draft the manuscript of this review, YY, WL and HZ edited the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Ke Xu or Xun Qi.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors agree with the final version of the manuscript and give their consent for its publication.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, P., Yuan, Y., Lin, W. et al. Roles of sphingosine-1-phosphate signaling in cancer. Cancer Cell Int 19, 295 (2019). https://doi.org/10.1186/s12935-019-1014-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12935-019-1014-8

Keywords

Cancer Cell International

ISSN: 1475-2867

Contact us